U of M study finds hydroxychloroquine shows no benefit in treating COVID-19

It was the first randomized clinical trial of hydroxychloroquine to treat non-hospitalized adults with COVID-19.
Author:
Publish date:

An anti-malaria drug that has been touted by President Donald Trump does not decrease the severity of COVID-19 symptoms, a new University of Minnesota study found. 

It was the first randomized clinical trial of hydroxychloroquine to treat non-hospitalized adults with COVID-19, and found the drug didn't decrease the severity of symptoms over 14 days any better than a placebo, a news release from the U of M said.

The results from U of M Medical School researchers were published in the Annals of Internal Medicine on Thursday. A previous U of M study found hydroxychloroquine has no benefit in preventing COVID-19.

The hope was the trial would offer an inexpensive, widely availably medication that could treat COVID-19 early on to help people avoid being hospitalized.

“This second randomized trial was conducted as a companion to our recently published hydroxychloroquine trial in the New England Journal of Medicine,” Caleb Skipper, MD, lead author on the paper and infectious diseases fellow, said in the release. “Taken together, there is no convincing evidence that hydroxychloroquine can either prevent COVID-19 after exposure or reduce illness severity after developing early symptoms.

"While disappointing, these results are consistent with an emerging body of literature that hydroxychloroquine doesn’t convey a substantial clinical benefit in people diagnosed with COVID-19 — despite its activity against the virus in a test tube," Skipper added. 

The double-blind trial, which launched March 22, involved 491 non-hospitalized adults from 40 states and three Canadian provinces, with participants being given either five days of hydroxychloroquine or five days of a placebo in the first few days of their symptoms.

The people in the trial were monitored for two weeks to see how quickly symptoms receded, as well as who was hospitalized, became seriously ill or died. 

After 14 days, 24 percent of trial participants (49 of 201 people) receiving hydroxychloroquine still had symptoms, while 30 percent (59 of 194 people) taking the placebo had symptoms. 

Of people taking hydroxychloroquine, four were hospitalized and one person died (they were not hospitalized). Of those taking the placebo, 10 people were hospitalized (two hospitalizations were not COVID-19-related) and one person died in the hospital. 

Next Up

bookkeeping-615384_1920

Money Gal Coaching: How jealousy stopped me from building wealth

Kelly started Money Gal Coaching after paying down more than $46,000 in debt in just 20 months.

police lights

Man arrested for kidnapping woman after standoff in Bloomington

A 42-year-old woman was being kept from her family, police said.

coast guard north station grand marais 1

US Coast Guard plans to close its Grand Marais station by next summer

The plan is to consolidate the seasonal station with the one in Duluth.

Flickr - Winston Smith memorial uptown June 4 - Chad Davis

Court documents reveal more details from Winston Smith death scene

Two weeks after his shooting, the circumstances remain murky.

police tape

'Human body parts' found in NE Minneapolis prompt homicide investigation

The body parts were discovered around 9:20 a.m. Thursday.

penumbra theatre company

3 Minnesota nonprofits get slice of $2.7B donated by Mackenzie Scott

The philanthropist has given away around $8 billion to nonprofits over the past year.

Screen Shot 2021-06-17 at 1.02.33 PM

Flights to resume between Minneapolis-St. Paul and Iceland

Icelandair is bringing back its service, which was nixed following the onset of COVID-19.

Juneteenth minneapolis

Communities across MN hosting events to mark Juneteenth

Juneteenth celebrates the freeing of enslaved African Americans after the Civil War.

Related

SARS-CoV-2, novel coronavirus

U of M study finds hydroxychloroquine drug doesn't prevent COVID-19

President Donald Trump has touted the drug and said he takes it.

Michael Osterholm

U of M's Osterholm named to President-elect Biden's COVID-19 advisory board

The board has prominent doctors and scientists tasked at guiding Biden's transition to president and planning for the federal response to the virus.

coronavirus, covid-19

U of M becomes among first to trial new COVID-19 treatment

They're treating a patient with lung failure using a new FDA-approved technique.

University of minnesota sign

Big crowds at U of M 'Superblock' spark COVID-19 concerns

The U says it's reviewing video of the incident, but students say the university isn't doing enough to protect students.

University of minnesota sign

U of M-Crookston imposes 9 p.m. student curfew to limit COVID-19 spread

It's designed to limit groups congregating at off-campus bars and parties.

Screen Shot 2020-10-02 at 9.49.09 AM

M Health Fairview implements chest X-rays to identify COVID-19

The X-ray is analyzed by an artificial intelligence algorithm, and it's already being used in Minnesota.

coronavirus, covid-19, doctor

U of M, Mayo Clinic testing provides hope for Minnesota in COVID-19 fight

Both institutions are in the process of preparing to deploy the tests to the public.

coronavirus, coronavirus test, covid-19

Studies look at potential scenarios for COVID-19 in Minnesota

Osterholm said the coronavirus "is going to touch every family in Minnesota."